SURUNKALI YURAK YETISHMOVCHILIGI BILAN KASALLANGAN BEMORLARDA HAYOT SIFATINI KOMPLEKS KLINIK VA NAZARIY TAHLILI
Keywords:
surunkali yurak yetishmovchiligi, hayot sifati, kardiologiya, mortalitet, kasallanish, yurak-qon tomir kasalliklari.Abstract
Surunkali yurak yetishmovchiligi zamonaviy kardiologiyaning eng dolzarb muammolaridan biri bo‘lib, kasallikning yuqori tarqalishi, nogironlikka olib kelishi hamda o‘lim ko‘rsatkichlarining yuqoriligi bilan ajralib turadi. Mazkur kasallik nafaqat yurak-qon tomir tizimi faoliyatining buzilishi, balki bemorlarning jismoniy, ruhiy va ijtimoiy hayot sifatining keskin pasayishiga ham sabab bo‘ladi. Ushbu maqolada surunkali yurak yetishmovchiligi bilan kasallangan bemorlarda hayot sifatini baholashning nazariy asoslari, kasallikning klinik kechishi va hayot sifatiga ta'sir etuvchi omillar ilmiy adabiyotlar asosida kompleks tahlil qilindi. Shuningdek, yurakning nasos funksiyasi pasayishi, neyrogumoral tizimlarning faollashuvi, yallig‘lanish mediatorlari, hamroh kasalliklar hamda psixoemotsional buzilishlarning bemorlarning kundalik faoliyati va funksional imkoniyatlariga ko‘rsatadigan ta'siri yoritildi. Dunyo va mintaqaviy epidemiologik ma'lumotlar asosida surunkali yurak yetishmovchiligining tarqalish dinamikasi, kasallanish va o‘lim ko‘rsatkichlari tahlil qilinib, hayot sifatini oshirishda zamonaviy davolash strategiyalari hamda multidissiplinar yondashuvning ilmiy ahamiyati asoslab berildi.
References
1. Bozkurt, B., Coats, A. J. S., Tsutsui, H., Abdelhamid, C. M., Adamopoulos, S., Albert, N., et al. (2021). Universal definition and classification of heart failure. Journal of Cardiac Failure, 27(4), 387–413.
2. Braunwald, E. (2022). Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (12th ed.). Elsevier.
3. Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation, 145(18), e895–e1032.
4. McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., et al. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 42(36), 3599–3726.
5. Savarese, G., & Lund, L. H. (2017). Global public health burden of heart failure. Cardiac Failure Review, 3(1), 7–11.
6. Ziaeian, B., & Fonarow, G. C. (2016). Epidemiology and aetiology of heart failure. Nature Reviews Cardiology, 13(6), 368–378.
7. Roger, V. L. (2021). Epidemiology of heart failure. Circulation Research, 128(10), 1421–1434.
8. Mann, D. L., Zipes, D. P., Libby, P., & Bonow, R. O. (2021). Braunwald's Heart Disease (12th ed.). Elsevier.
9. Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., et al. (2017). 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment. Journal of the American College of Cardiology, 70(6), 713–734.
10. Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., et al. (2016). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), 2129–2200.
11. World Health Organization. (2023). Cardiovascular diseases (CVDs). Geneva: World Health Organization.
12. Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., et al. (2024). Heart Disease and Stroke Statistics—2024 Update. Circulation, 149(8), e347–e913.
13. Greene, S. J., Butler, J., Albert, N. M., DeVore, A. D., Sharma, P. P., Duffy, C. I., et al. (2018). Medical therapy for heart failure with reduced ejection fraction. Journal of the American College of Cardiology, 72(4), 351–366.
14. McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381(21), 1995–2008.
15. Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., et al. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 383(15), 1413–1424.
16. Bekelman, D. B., Rumsfeld, J. S., Havranek, E. P., Yamashita, T. E., Hutt, E., Gottlieb, S. H., et al. (2007). Symptom burden, depression, and spiritual well-being in heart failure. Journal of General Internal Medicine, 22(5), 592–598.
17. Lewis, E. F., Lamas, G. A., O'Meara, E., Granger, C. B., Dunlap, M. E., McKelvie, R. S., et al. (2007). Characterization of health-related quality of life in heart failure. Circulation, 115(1), 59–66.
18. Jaarsma, T., Cameron, J., Riegel, B., & Stromberg, A. (2017). Factors related to self-care in heart failure patients. Journal of Cardiovascular Nursing, 32(1), 21–30.
19. Dunlay, S. M., Roger, V. L., & Redfield, M. M. (2017). Epidemiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology, 14(10), 591–602.
20. Pfeffer, M. A., Shah, A. M., & Borlaug, B. A. (2019). Heart failure with preserved ejection fraction in perspective. Circulation Research, 124(11), 1598–1617.
O‘zbekiston Respublikasi, Andijon viloyati, Shahrixon tumani
(+998) 945668868